Article, 2024
Primary gastric diffuse large B‐cell lymphoma: A multicentre retrospective study
British Journal of Haematology,
ISSN
1365-2141,
0007-1048,
10.1111/bjh.19470
Contributors
Lewis, Cameron Scott
0000-0003-4137-8096
[1]
[2]
Joy, Greta
[3]
[4]
Jensen, Paw
0000-0002-5248-0523
[5]
Barraclough, Allison Anne
0000-0003-1615-0540
[6]
[7]
Franco, Nunzio Francesco
[8]
Talaulikar, Dipti
0000-0001-6766-8345
[8]
[9]
Hawkes, Eliza Anne
0000-0002-0376-2559
[7]
[10]
El-Galaly, Tarec Christoffer Christoffer
0000-0002-4406-380X
[5]
[11]
[12]
Villa, Diego R
[4]
Dickinson, Michael J
0000-0002-1492-5966
[1]
[13]
Seymour, John Francis
0000-0003-2188-6835
[1]
[13]
Cheah, Chan Yoon Y
0000-0001-7988-1565
(Corresponding author)
[2]
Affiliations
- [1]
Royal Melbourne Hospital
[NORA names:
Australia; Oceania; OECD];
- [2]
Sir Charles Gairdner Hospital
[NORA names:
Australia; Oceania; OECD];
- [3]
University of British Columbia
[NORA names:
Canada; America, North; OECD];
- [4]
BC Cancer Agency
[NORA names:
Canada; America, North; OECD];
- [5]
Aalborg University Hospital
[NORA names:
North Denmark Region; Hospital; Denmark; Europe, EU; Nordic; OECD];
(... more)
- [6]
Fiona Stanley Hospital
[NORA names:
Australia; Oceania; OECD];
- [7]
Austin Health
[NORA names:
Australia; Oceania; OECD];
- [8]
Department of Haematology, ACT Pathology, Canberra Health Services, Canberra, Australian Capital Territory, Australia
[NORA names:
Australia; Oceania; OECD];
- [9]
Australian National University
[NORA names:
Australia; Oceania; OECD];
- [10]
Monash University
[NORA names:
Australia; Oceania; OECD];
- [11]
Karolinska Institutet
[NORA names:
Sweden; Europe, EU; Nordic; OECD];
- [12]
Odense University Hospital
[NORA names:
Region of Southern Denmark;
Hospital; Denmark; Europe, EU; Nordic; OECD];
- [13]
University of Melbourne
[NORA names:
Australia; Oceania; OECD]
(less)
Abstract
Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71-95) and 91% (95% CI: 75-97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.
Keywords
Australia,
B-cell lymphoma,
Canada,
DLBCL,
Denmark,
H. pylori,
H. pylori eradication therapy,
I disease,
PG-DLBCL,
R-CHOP,
assessment,
centre,
characterise outcomes,
chemoimmunotherapy,
cohort,
cohort of patients,
complete metabolic response,
consolidation radiotherapy,
cyclophosphamide,
diffuse large B-cell lymphoma,
documents,
doxorubicin,
duration of follow-up,
emission tomography,
eradication therapy,
favorable outcome,
follow-up,
gastric diffuse large B-cell lymphoma,
goal,
interim positron emission tomography,
large B-cell lymphoma,
literature,
lymphoma,
median duration,
median duration of follow-up,
metabolic response,
months,
outcomes,
overall survival,
partial metabolic response,
patients,
positron emission tomography,
prednisolone,
presentation,
primary gastric diffuse large B-cell lymphoma,
progression-free survival,
radiotherapy,
response,
review,
review treatment,
rituximab,
stage,
stage I disease,
survival,
therapy,
tomography,
treatment,
vincristine
Data Provider: Digital Science